Suchen
LB Pharmaceuticals Inc
LBRXZur Watchlist hinzufügen
29.660USD
-1.750-5.57%
Handelsschluss 05/15, 16:00（ET）Kurse um 15 Minuten verzögert
850.55MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über LB Pharmaceuticals Inc Unternehmen
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a Phase III-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms, characterized by hallucinations, delusions, and other positive symptoms. The Company is also developing a long-acting injectable, or LAI, formulation of LB-102, which improves compliance, a common issue in patients with schizophrenia and bipolar disorder.
LB Pharmaceuticals Inc Informationen
BörsenkürzelLBRX
Name des UnternehmensLB Pharmaceuticals Inc
IPO-datumSep 11, 2025
CEOTurner (Heather D)
Anzahl der mitarbeiter16
WertpapierartOrdinary Share
GeschäftsjahresendeSep 11
AddresseOne Pennsylvania Plaza, Suite 1025
StadtNEW YORK
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl10119
Telefon19174506581
Websitehttps://lbpharma.us/
BörsenkürzelLBRX
IPO-datumSep 11, 2025
CEOTurner (Heather D)
Führungskräfte von LB Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Zachary Prensky
Mr. Zachary Prensky
Co-Founder, Director
Co-Founder, Director
61.27K
--
Mr. Marc L. Panoff, CPA
Mr. Marc L. Panoff, CPA
Senior Vice President - Finance
Senior Vice President - Finance
10.24K
--
Ms. Heather D. Turner, J.D.
Ms. Heather D. Turner, J.D.
Chief Executive Officer, Member of our Board of Director
Chief Executive Officer, Member of our Board of Director
--
--
Mr. Gad Soffer
Mr. Gad Soffer
Chief Business Officer
Chief Business Officer
--
--
Dr. Anna Eramo, M.D.
Dr. Anna Eramo, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Richard Silva, Ph.D.
Mr. Richard Silva, Ph.D.
Senior Vice President of Technical Operations
Senior Vice President of Technical Operations
--
--
Mr. Scott Garland
Mr. Scott Garland
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Rajul Jain, M.D.
Dr. Rajul Jain, M.D.
Independent Director
Independent Director
--
--
Ms. Rebecca Luse
Ms. Rebecca Luse
Independent Director
Independent Director
--
--
Mr. Ran Nussbaum
Mr. Ran Nussbaum
Independent Director
Independent Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Zachary Prensky
Mr. Zachary Prensky
Co-Founder, Director
Co-Founder, Director
61.27K
--
Mr. Marc L. Panoff, CPA
Mr. Marc L. Panoff, CPA
Senior Vice President - Finance
Senior Vice President - Finance
10.24K
--
Ms. Heather D. Turner, J.D.
Ms. Heather D. Turner, J.D.
Chief Executive Officer, Member of our Board of Director
Chief Executive Officer, Member of our Board of Director
--
--
Mr. Gad Soffer
Mr. Gad Soffer
Chief Business Officer
Chief Business Officer
--
--
Dr. Anna Eramo, M.D.
Dr. Anna Eramo, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Richard Silva, Ph.D.
Mr. Richard Silva, Ph.D.
Senior Vice President of Technical Operations
Senior Vice President of Technical Operations
--
--
Umsatzaufteilung
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, May 10
Aktualisiert: Sun, May 10
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Deep Track Capital LP
11.69%
RA Capital Management, LP
7.70%
TCG Crossover Management, LLC
6.41%
Trails Edge Capital Partners LP
6.03%
Commodore Capital LP
5.23%
Andere
62.94%
Aktionäre
Aktionäre
Anteil
Deep Track Capital LP
11.69%
RA Capital Management, LP
7.70%
TCG Crossover Management, LLC
6.41%
Trails Edge Capital Partners LP
6.03%
Commodore Capital LP
5.23%
Andere
62.94%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
32.30%
Hedge Fund
27.72%
Venture Capital
23.79%
Investment Advisor/Hedge Fund
10.52%
Institution
2.32%
Research Firm
1.44%
Individual Investor
0.27%
Bank and Trust
0.24%
Sovereign Wealth Fund
0.07%
Andere
1.32%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q4
62
22.24M
0.00%
--
2026Q1
134
28.68M
100.01%
+5.56M
2025Q4
81
25.18M
99.53%
+24.44M
2025Q3
10
12.02M
47.50%
+12.02M
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Deep Track Capital LP
3.35M
11.69%
--
--
Feb 06, 2026
RA Capital Management, LP
2.21M
7.7%
+431.65K
+24.29%
Dec 31, 2025
TCG Crossover Management, LLC
1.75M
6.09%
-1.00
-0.00%
Dec 31, 2025
Trails Edge Capital Partners LP
1.40M
4.87%
+1.40M
--
Dec 31, 2025
Commodore Capital LP
1.50M
5.23%
--
--
Dec 31, 2025
Pontifax Venture Capital
1.41M
4.92%
+1.41M
--
Sep 12, 2025
JP Morgan Asset Management
1.35M
4.7%
+468.57K
+53.37%
Dec 31, 2025
Logos Global Management LP
1.20M
4.18%
+70.00K
+6.19%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
1.18M
4.12%
+1.18M
+132523.57%
Dec 31, 2025
Spruce Street Capital LP
1.01M
3.51%
+1.01M
--
Dec 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
